KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Shares Issued (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Shares Issued for 18 consecutive years, with $163.1 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Issued rose 169.14% year-over-year to $163.1 million; the TTM value through Mar 2026 reached $738.4 million, down 12.49%, while the annual FY2025 figure was $635.9 million, 56.6% down from the prior year.
  • Shares Issued hit $163.1 million in Q1 2026 for Regeneron Pharmaceuticals, down from $503.5 million in the prior quarter.
  • Across five years, Shares Issued topped out at $682.1 million in Q1 2024 and bottomed at $31.5 million in Q2 2025.
  • Average Shares Issued over 5 years is $290.0 million, with a median of $301.0 million recorded in 2023.
  • On a YoY basis, Shares Issued climbed as much as 453.91% in 2025 and fell as far as 92.8% in 2025.
  • Regeneron Pharmaceuticals' Shares Issued stood at $372.6 million in 2022, then dropped by 19.22% to $301.0 million in 2023, then crashed by 69.8% to $90.9 million in 2024, then soared by 453.91% to $503.5 million in 2025, then plummeted by 67.61% to $163.1 million in 2026.
  • According to Business Quant data, Shares Issued over the past three periods came in at $163.1 million, $503.5 million, and $40.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.